Literature DB >> 11328309

Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience.

G Stussi1, L Seebach, J Muntwyler, U Schanz, J Gmür, J D Seebach.   

Abstract

The effect of ABO-incompatibility on graft versus host disease (GVHD) and survival was evaluated in 173 consecutive patients receiving allogeneic bone marrow transplantation (BMT). Thirty-four percent of the patients developed GVHD and univariate analysis suggested a higher incidence of GVHD in minor ABO-incompatibility than in ABO-identity (14/30, 47% versus 37/112, 33%; P = 0.02). However, using logistic regression adjusted for potential confounders, the GVHD risk did not differ significantly. During a mean follow-up time of 59 months, the mortality was 37% and survival was significantly dependent on ABO-compatibility (P = 0.004). In particular, patients with bidirectional ABO-incompatibility had an excess mortality rate (RR, 7.6; 95% CI, 2.5-23.2; P = 0.0004). Taken together, these results suggest that ABO-incompatibility may represent a risk factor in allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328309     DOI: 10.1046/j.1365-2141.2001.02734.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  The processing of stem cell concentrates from the bone marrow in ABO-incompatible transplants: how and when.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Cecilia Rossi; Alessandro Lanti; Gaspare Adorno; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2013-11-21       Impact factor: 3.443

2.  The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.

Authors:  Roberta Fedele; Massimo Martino; Cristina Garreffa; Giuseppe Messina; Giuseppe Console; Domenica Princi; Antonella Dattola; Tiziana Moscato; Elisabetta Massara; Elisa Spiniello; Giuseppe Irrera; Pasquale Iacopino
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

3.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Authors:  Zejing Wang; Mohamed L Sorror; Wendy Leisenring; Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Br J Haematol       Date:  2010-01-11       Impact factor: 6.998

4.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

5.  ABO Incompatibility and Hematopoietic Stem Cell Transplantation Outcomes.

Authors:  Mohammad Vaezi; Davoud Oulad Dameshghi; Maryam Souri; Seyed Amin Setarehdan; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-04-01

6.  Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study.

Authors:  José Alfreu Soares Júnior; Glaucia Helena Martinho; Antonio Vaz de Macedo; Marisa Ribeiro Verçosa; Vandack Nobre; Gustavo Machado Teixeira
Journal:  Hematol Transfus Cell Ther       Date:  2018-07-10

7.  Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques.

Authors:  Robert Sheppard Nickel; Muna Qayed; Diana Worthington-White; Sean R Stowell; Kuang-Yueh Chiang
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.838

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.